The company is aiming to create a suite of products that can help researchers and manufacturers engineer various genomes at scale for multiple purposes.
The investment bank gave Danaher a Neutral rating and a $148 price target on the firm's shares, while it gave Agilent an Overweight rating with an $83 price target.
Evercore analysts set a price target of $30.50 for the company and said they see opportunities in DNA synthesis, NGS tools, pharmaceuticals, and DNA data storage.
In Nature this week: synthetic Escherichia coli genome with fewer codons, and more.
The company will offer 3.75 million shares of its common stock at $21 per share.
The company will use the proceeds to expand its R&D capabilities and its commercial operations.
During the second quarter of fiscal 2019, the firm took orders for genes, libraries, and oligonucleotide pools from about 780 customers.
For the quarter ended March 31, Twist reported $13.6 million in revenues, up from $6.2 million during the same period last year.
The company launched last month with initial financing of $35 million and licenses to CRISPR and synthetic biology technology from the Broad and Harvard.
The partnership follows a strategic collaboration between Twist and LakePharma, announced last week, that involves the same technology.
A new analysis finds some cancers receive more nonprofit dollars than others.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
In Science this week: comparative analysis of sex differences in mammal gene expression, and more.